Insulin Affordability Data Collection Act

Bill: 116-s-2855
Sponsor: full_name: Sen. Smith, Tina [D-MN]
Introduced: 2019-11-14
Policy area: Health
Subjects: Congressional oversight

Digestive and metabolic diseases

Employee benefits and pensions

Government studies and investigations

Health care costs and insurance

Health care coverage and access

Health programs administration and funding

Medicaid

Medical research

Prescription drugs
Latest action: action_date: 2019-11-14
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2019-11-14
action_desc: Introduced in Senate
text: <p><b>Insulin Affordability Data Collection Act</b><br> <br> This bill requires the Department of Health and Human Services to conduct a study evaluating the impact of insulin affordability on the health outcomes of individuals who are reliant on insulin. </p>

tv_txt: II 116th CONGRESS 1st Session S. 2855 IN THE SENATE OF THE UNITED STATES November 14, 2019 Ms. Smith (for herself, Mr. Cramer , Ms. Baldwin , Mrs. Hyde-Smith , Mr. Durbin , and Mr. Wicker ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Secretary to conduct a study and issue a report on the affordability of insulin.

1. Short title This Act may be cited as the Insulin Affordability Data Collection Act . 2. Study and report on the affordability of insulin The Secretary of Health and Human Services (referred to in this section as the Secretary ), acting through the Assistant Secretary for Planning and Evaluation, shall— (1) conduct a study that examines— (A) for each type or classification of diabetes (including type 1 diabetes, type 2 diabetes, gestational diabetes, and other conditions causing reliance on insulin), the effect of the affordability of insulin on— (i) adherence to insulin prescriptions; (ii) rates of diabetic ketoacidosis; (iii) downstream impacts of insulin adherence, including rates of dialysis treatment and end-stage renal disease; (iv) spending by Federal health programs on acute episodes that could have been averted by adhering to an insulin prescription; and (v) other factors, as appropriate, to understand the impacts of insulin affordability on health outcomes, Federal Government spending (including under the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq.) and the Medicaid program under title XIX of the Social Security Act ( 42 U.S.C. 1396 et seq.)), and insured and uninsured individuals with diabetes; and (B) among individuals who are unable to afford insulin, the numbers of such individuals— (i) who are uninsured; (ii) who are covered under private health insurance; and (iii) who are covered under public health insurance programs; and (2) not later than 2 years after the date of enactment of this Act, submit to Congress a report on the study conducted under paragraph (1).